287 related articles for article (PubMed ID: 12664611)
1. Mechanism of inhibition of novel COX-2 inhibitors.
Gierse J; Kurumbail R; Walker M; Hood B; Monahan J; Pawlitz J; Stegeman R; Stevens A; Kiefer J; Koboldt C; Moreland K; Rowlinson S; Marnett L; Pierce J; Carter J; Talley J; Isakson P; Seibert K
Adv Exp Med Biol; 2002; 507():365-9. PubMed ID: 12664611
[No Abstract] [Full Text] [Related]
2. Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
Hood WF; Gierse JK; Isakson PC; Kiefer JR; Kurumbail RG; Seibert K; Monahan JB
Mol Pharmacol; 2003 Apr; 63(4):870-7. PubMed ID: 12644588
[TBL] [Abstract][Full Text] [Related]
3. COX-2 inhibitors--is there cause for concern?
Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
[No Abstract] [Full Text] [Related]
4. Coming: a review of second-generation nonsteroidal anti-inflammatory drugs.
Housholder GT; Chan JT
J Gt Houst Dent Soc; 1997 Mar; 68(8):13-6. PubMed ID: 9594801
[No Abstract] [Full Text] [Related]
5. [Topical pharmacology. COX-2 inhibitors].
Heinzl S
Med Monatsschr Pharm; 1999 Oct; 22(10):298-304. PubMed ID: 10540801
[No Abstract] [Full Text] [Related]
6. Do COX-2 inhibitors reduce renal fibrosis?
Harding P
J Hypertens; 2004 Jan; 22(1):43-5. PubMed ID: 15106792
[No Abstract] [Full Text] [Related]
7. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord.
Tegeder I; Niederberger E; Vetter G; Bräutigam L; Geisslinger G
J Neurochem; 2001 Nov; 79(4):777-86. PubMed ID: 11723170
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological analysis of cyclooxygenase-1 in inflammation.
Smith CJ; Zhang Y; Koboldt CM; Muhammad J; Zweifel BS; Shaffer A; Talley JJ; Masferrer JL; Seibert K; Isakson PC
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13313-8. PubMed ID: 9789085
[TBL] [Abstract][Full Text] [Related]
9. Human and rat cyclooxygenases are pharmacologically distinct.
Ramesha CS
Adv Exp Med Biol; 1997; 407():67-71. PubMed ID: 9321933
[No Abstract] [Full Text] [Related]
10. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
Kardosh A; Blumenthal M; Wang WJ; Chen TC; Schönthal AH
Cancer Biol Ther; 2004 Jan; 3(1):55-62. PubMed ID: 14726653
[TBL] [Abstract][Full Text] [Related]
11. [Selective cyclooxygenase 2 inhibitors (COX-2)].
Mejza F; Nizankowska E
Postepy Hig Med Dosw; 2001; 55(2):287-302. PubMed ID: 11468975
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for selective inhibition of COX-2 by nimesulide.
Fabiola GF; Pattabhi V; Nagarajan K
Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic advances with coxibs: few certainties and a lot of doubts].
Jouzeau JY; Daouphars M; Netter P
Therapie; 2004; 59(2):207-11. PubMed ID: 15359614
[No Abstract] [Full Text] [Related]
14. First and second generations of COX-2 selective inhibitors.
de Leval X; Julémont F; Benoit V; Frederich M; Pirotte B; Dogné JM
Mini Rev Med Chem; 2004 Aug; 4(6):597-601. PubMed ID: 15279593
[TBL] [Abstract][Full Text] [Related]
15. [APHS and celecoxib, the new aspirins have arrived].
Bénard J
Bull Cancer; 1998 Jul; 85(7):605. PubMed ID: 9752265
[No Abstract] [Full Text] [Related]
16. COX in a crystal ball: current status and future promise of prostaglandin research.
FitzGerald GA; Loll P
J Clin Invest; 2001 Jun; 107(11):1335-7. PubMed ID: 11390412
[No Abstract] [Full Text] [Related]
17. Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice.
Wormser U; Langenbach R; Peddada S; Sintov A; Brodsky B; Nyska A
Toxicol Appl Pharmacol; 2004 Oct; 200(1):40-7. PubMed ID: 15451306
[TBL] [Abstract][Full Text] [Related]
18. Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors.
Singh SK; Vobbalareddy S; Shivaramakrishna S; Krishnamraju A; Rajjak SA; Casturi SR; Akhila V; Rao YK
Bioorg Med Chem Lett; 2004 Apr; 14(7):1683-8. PubMed ID: 15026050
[TBL] [Abstract][Full Text] [Related]
19. COX-1 sparing and COX-2 inhibitory drugs: the renal and hepatic safety and tolerability profiles of celecoxib.
Whelton A
Am J Ther; 2000 May; 7(3):151-2. PubMed ID: 11317163
[No Abstract] [Full Text] [Related]
20. [Progress in the study of cyclooxygenase].
Zhu H; Yang ZM
Sheng Li Ke Xue Jin Zhan; 2004 Jan; 35(1):81-3. PubMed ID: 15127608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
